Aligned with FDA on dual-trial design Phase 3 program that aims to demonstrate robust efficacy and long-term safety and that allows for flexible ...

纽约 - AtaiBeckley Inc. (NASDAQ:ATAI) 今日宣布,美国食品药品监督管理局已表示支持该公司针对BPL-003的拟议3期项目,BPL-003是一种鼻内给药的苯甲酸美布替宁制剂,用于治疗难治性抑郁症,根据新闻稿声明。

ATAI, has completed its merger with Beckley Psytech, bringing lead compound BPL-003 fully in house. BPL-003 has received FDA Breakthrough Therapy designation for treatment resistant depression. Recent ...

The Bangladesh Premier League (BPL) has survived a series of stumbles and mis-steps to get into its 12th year. As it begins, there are serious questions about the tournament's integrity, the quality ...